文献速递癫痫

耐药性癫痫患者中推荐神经诊断评估的使用情况

Use of Recommended Neurodiagnostic Evaluation Among Patients With Drug-Resistant Epilepsy.
PubMed 文献 · JAMA Neurol · 2024-01-01

这项回顾性横断面研究利用美国多州医疗补助、商业保险和哥伦比亚大学医学中心电子健康记录数据,纳入2015年1月1日至2020年4月1日间符合耐药性癫痫计算表型的患者,评估2年内完成综合神经诊断评估(脑磁共振或其他先进影像、视频脑电图、神经心理评估)的比例及相关因素,发现各队列评估完成率均低,就诊频率和局灶性癫痫与更高评估几率相关。

要点

  • 医疗补助队列综合评估完成率为4.5%,商业保险队列为8.0%,哥伦比亚大学医学中心队列为14.3%。
  • 视频脑电图和脑磁共振的执行率高于神经心理评估和先进影像。
  • 住院和门诊非急诊癫痫就诊次数及局灶性而非全面性癫痫与更高的评估几率独立相关。

核心结论

  • 研究结果表明,在评估耐药性癫痫患者时诊断性检查的使用存在差距。
  • 就诊环境、保险类型、非急诊就诊频率和癫痫类型均与评估相关。

研究设计与样本

  • 回顾性横断面研究,使用观察性医疗结果合作组织通用数据模型,包括美国多州医疗补助数据、商业索赔数据和哥伦比亚大学医学中心电子健康记录数据。
  • 纳入2015年1月1日至2020年4月1日间符合经验证的耐药性癫痫计算表型算法的患者,未排除任何合格参与者。
  • 医疗补助队列33 542例,商业保险队列22 496例,哥伦比亚大学医学中心数据库2741例;31 516例(53.6%)为女性。

主要发现

  • 达到综合评估主要结局的比例:医疗补助队列4.5%(n=1520),商业保险队列8.0%(n=1796),哥伦比亚大学医学中心队列14.3%(n=393)。
  • 视频脑电图执行率:医疗补助24.9%,商业保险28.4%,哥伦比亚大学医学中心63.2%。
  • 脑磁共振执行率:医疗补助35.6%,商业保险43.4%,哥伦比亚大学医学中心52.6%。
  • 神经心理评估执行率:医疗补助13.0%,商业保险16.6%,哥伦比亚大学医学中心19.2%。
  • 先进影像执行率:医疗补助3.2%,商业保险5.4%,哥伦比亚大学医学中心13.1%。

关键数值与推荐

  • 综合神经诊断评估的复合替代指标包括:在符合纳入标准后2年内进行(1)磁共振或其他先进脑影像,(2)视频脑电图,(3)神经心理评估。
  • 在所有3个数据集中与更高评估几率独立相关的因素包括:住院和门诊非急诊癫痫就诊次数,以及局灶性而非全面性癫痫。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Interdisciplinary practice parameters recommend that patients with drug-resistant epilepsy (DRE) undergo comprehensive neurodiagnostic evaluation, including presurgical assessment. Reporting from specialized centers suggests long delays to referral and underuse of surgery; however, longitudinal data are limited to characterize neurodiagnostic evaluation among patients with DRE in more diverse US settings and populations. OBJECTIVE: To examine the rate and factors associated with neurodiagnostic studies and comprehensive evaluation among patients with DRE within 3 US cohorts. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cross-sectional study was conducted using the Observational Medical Outcomes Partnership Common Data Model including US multistate Medicaid data, commercial claims data, and Columbia University Medical Center (CUMC) electronic health record data. Patients meeting a validated computable phenotype algorithm for DRE between January 1, 2015, and April 1, 2020, were included. No eligible participants were excluded. EXPOSURE: Demographic and clinical variables were queried. MAIN OUTCOMES AND MEASURES: The proportion of patients receiving a composite proxy for comprehensive neurodiagnostic evaluation, including (1) magnetic resonance or other advanced brain imaging, (2) video electroencephalography, and (3) neuropsychological evaluation within 2 years of meeting the inclusion criteria. RESULTS: A total of 33 542 patients with DRE were included in the Medicaid cohort, 22 496 in the commercial insurance cohort, and 2741 in the CUMC database. A total of 31 516 patients (53.6%) were women. The proportion of patients meeting the comprehensive evaluation main outcome in the Medicaid cohort was 4.5% (n = 1520); in the commercial insurance cohort, 8.0% (n = 1796); and in the CUMC cohort, 14.3% (n = 393). Video electroencephalography (24.9% Medicaid, 28.4% commercial, 63.2% CUMC) and magnetic resonance imaging of the brain (35.6% Medicaid, 43.4% commercial, 52.6% CUMC) were performed more regularly than neuropsychological evaluation (13.0% Medicaid, 16.6% commercial, 19.2% CUMC) or advanced imaging (3.2% Medicaid, 5.4% commercial, 13.1% CUMC). Factors independently associated with greater odds of evaluation across all 3 data sets included the number of inpatient and outpatient nonemergency epilepsy visits and focal rather than generalized epilepsy. CONCLUSIONS AND RELEVANCE: The findings of this study suggest there is a gap in the use of diagnostic studies to evaluate patients with DRE. Care setting, insurance type, frequency of nonemergency visits, and epilepsy type are all associated with evaluation. A common data model can be used to measure adherence with best practices across a variety of observational data sources.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Spotnitz M, Ekanayake CD, Ostropolets A, et al. Use of Recommended Neurodiagnostic Evaluation Among Patients With Drug-Resistant Epilepsy. JAMA Neurol. 2024. PMID: 38557864. doi:10.1001/jamaneurol.2024.0551

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。